{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:12:59Z","timestamp":1791519179110,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,8]]},"DOI":"10.7759\/cureus.27773","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T12:47:02Z","timestamp":1659962822000},"source":"Crossref","is-referenced-by-count":16,"title":["Fournier\u2019s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy"],"prefix":"10.7759","author":[{"given":"Tutul","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Gousy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amulya","family":"Bellamkonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chowdhury F","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummul B","family":"Zakia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasniem","family":"Tasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyata","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmaja","family":"Deb Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana  M","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Mainali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10092036","article-title":"SGLT2 inhibitors, what the emergency physician needs to know: a narrative review","volume":"10","author":"Lu H","year":"2021","unstructured":"Lu H, Lu H, Kosinski C, et al.. SGLT2 inhibitors, what the emergency physician needs to know: a narrative review. J Clin Med. 2021, 10:10.3390\/jcm10092036","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00771-8","article-title":"SGLT2 inhibitors and the risk of hospitalization for Fournier's gangrene: a nested case-control study","volume":"11","author":"Wang T","year":"2020","unstructured":"Wang T, Patel SM, Hickman A, Liu X, Jones PL, Gantz I, Koro CE. SGLT2 inhibitors and the risk of hospitalization for Fournier's gangrene: a nested case-control study. Diabetes Ther. 2020, 11:711-23. 10.1007\/s13300-020-00771-8","journal-title":"Diabetes Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18948","article-title":"Fournier's gangrene diagnosis and treatment: a systematic review","volume":"13","author":"Lewis GD","year":"2021","unstructured":"Lewis GD, Majeed M, Olang CA, Patel A, Gorantla VR, Davis N, Gluschitz S. Fournier's gangrene diagnosis and treatment: a systematic review. Cureus. 2021, 13:e18948. 10.7759\/cureus.18948","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha SJ","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019, 170:764-9. 10.7326\/M19-0085","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0846537119888396","article-title":"Fournier gangrene in men and women: appearance on CT, ultrasound, and MRI and what the surgeon wants to know","volume":"71","author":"Ballard DH","year":"2020","unstructured":"Ballard DH, Mazaheri P, Raptis CA, Lubner MG, Menias CO, Pickhardt PJ, Mellnick VM. Fournier gangrene in men and women: appearance on CT, ultrasound, and MRI and what the surgeon wants to know. Can Assoc Radiol J. 2020, 71:30-9. 10.1177\/0846537119888396","journal-title":"Can Assoc Radiol J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/NUR.0000000000000423","article-title":"Sodium-glucose cotransporter 2 inhibitors and Fournier gangrene: a rare and lethal adverse event","volume":"33","author":"O'Malley PA","year":"2019","unstructured":"O'Malley PA. Sodium-glucose cotransporter 2 inhibitors and Fournier gangrene: a rare and lethal adverse event. Clin Nurse Spec. 2019, 33:63-5. 10.1097\/NUR.0000000000000423","journal-title":"Clin Nurse Spec"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris A","year":"2019","unstructured":"Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health. 2019, 16:10.3390\/ijerph16162965","journal-title":"Int J Environ Res Public Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink HJ","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016, 134:752-72. 10.1161\/CIRCULATIONAHA.116.021887","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3695101","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA Adverse Event Reporting System","volume":"2020","author":"Hu Y","year":"2020","unstructured":"Hu Y, Bai Z, Tang Y, Liu R, Zhao B, Gong J, Mei D. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA Adverse Event Reporting System. J Diabetes Res. 2020, 2020:3695101. 10.1155\/2020\/3695101","journal-title":"J Diabetes Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown E","year":"2021","unstructured":"Brown E, Heerspink HJ, Cuthbertson DJ, Wilding JP. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021, 398:262-276. 10.1016\/S0140-6736(21)00536-5","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/942437","article-title":"Fournier's gangrene: current practices","volume":"2012","author":"Mallikarjuna MN","year":"2012","unstructured":"Mallikarjuna MN, Vijayakumar A, Patil VS, Shivswamy BS. Fournier's gangrene: current practices. ISRN Surg. 2012, 2012:942437. 10.5402\/2012\/942437","journal-title":"ISRN Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/TME.0000000000000221","article-title":"Recognizing Fournier's gangrene in the emergency department","volume":"41","author":"Gadler T","year":"2019","unstructured":"Gadler T, Huey S, Hunt K. Recognizing Fournier's gangrene in the emergency department. Adv Emerg Nurs J. 2019, 41:33-8. 10.1097\/TME.0000000000000221","journal-title":"Adv Emerg Nurs J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-014-0783-8","article-title":"The evaluation of microbiology and prognosis of fournier's gangrene in past five years","volume":"4","author":"Tang LM","year":"2015","unstructured":"Tang LM, Su YJ, Lai YC. The evaluation of microbiology and prognosis of fournier's gangrene in past five years. Springerplus. 2015, 4:14. 10.1186\/s40064-014-0783-8","journal-title":"Springerplus"},{"key":"ref14","unstructured":"FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. (2018). Accessed. June 1, 2022: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-are...."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0570-3","article-title":"Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome","volume":"50","author":"Benfield T","year":"2007","unstructured":"Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007, 50:549-54. 10.1007\/s00125-006-0570-3","journal-title":"Diabetologia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000490108","article-title":"Fournier\u2019s gangrene: literature review and clinical cases","volume":"101","author":"Chernyadyev SA","year":"2018","unstructured":"Chernyadyev SA, Ufimtseva MA, Vishnevskaya IF, et al.. Fournier\u2019s gangrene: literature review and clinical cases. Urol Int. 2018, 101:91-7. 10.1159\/000490108","journal-title":"Urol Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2020.11.100","article-title":"Fournier's gangrene under SGLT-2 inhibitor therapy: a literature review and case report","volume":"77","author":"Elleg\u00e5rd L","year":"2020","unstructured":"Elleg\u00e5rd L, Prytz M. Fournier's gangrene under SGLT-2 inhibitor therapy: a literature review and case report. Int J Surg Case Rep. 2020, 77:692-4. 10.1016\/j.ijscr.2020.11.100","journal-title":"Int J Surg Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.endinu.2019.12.007","article-title":"Fournier's gangrene and SGLT2 inhibitors: a case study","volume":"67","author":"Garc\u00eda-Garc\u00eda A","year":"2020","unstructured":"Garc\u00eda-Garc\u00eda A, Galeano-Valle F, Nuevo-Gonz\u00e1lez JA, Demelo-Rodr\u00edguez P. Fournier's gangrene and SGLT2 inhibitors: a case study. Endocrinol Diabetes Nutr (Engl Ed). 2020, 67:423-5. 10.1016\/j.endinu.2019.12.007","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-01010-6","article-title":"Potential safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease","volume":"43","author":"Milder TY","year":"2020","unstructured":"Milder TY, Stocker SL, Day RO, Greenfield JR. Potential safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease. Drug Saf. 2020, 43:1211-21. 10.1007\/s40264-020-01010-6","journal-title":"Drug Saf"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5173","article-title":"Early presentation of a rare complication of sodium-glucose cotransporter-2 inhibitors 10 days after initiation: case report and literature review","volume":"11","author":"Elshimy G","year":"2019","unstructured":"Elshimy G, Correa R, Alsayed M, Jyothinagaram S. Early presentation of a rare complication of sodium-glucose cotransporter-2 inhibitors 10 days after initiation: case report and literature review. Cureus. 2019, 11:e5173. 10.7759\/cureus.5173","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18192\/uojm.v9i2.4476","article-title":"Bitter sweet: Fournier\u2019s Gangrene and SGLT2 inhibitors","volume":"9","author":"Kappel C","year":"2019","unstructured":"Kappel C. Bitter sweet: Fournier\u2019s Gangrene and SGLT2 inhibitors. Univ Ottawa J Med. 2019, 9:52-54. 10.18192\/uojm.v9i2.4476","journal-title":"Univ Ottawa J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/OAEM.S238699","article-title":"Fournier gangrene in the emergency department: diagnostic dilemmas, treatments and current perspectives","volume":"12","author":"Auerbach J","year":"2020","unstructured":"Auerbach J, Bornstein K, Ramzy M, Cabrera J, Montrief T, Long B. Fournier gangrene in the emergency department: diagnostic dilemmas, treatments and current perspectives. Open Access Emerg Med. 2020, 12:353-64. 10.2147\/OAEM.S238699","journal-title":"Open Access Emerg Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.921536","article-title":"Fournier's gangrene and diabetic ketoacidosis associated with sodium glucose co-transporter 2 (SGLT2) inhibitors: life-threatening complications","volume":"21","author":"Kasbawala K","year":"2020","unstructured":"Kasbawala K, Stamatiades GA, Majumdar SK. Fournier's gangrene and diabetic ketoacidosis associated with sodium glucose co-transporter 2 (SGLT2) inhibitors: life-threatening complications. Am J Case Rep. 2020, 21:e921536. 10.12659\/AJCR.921536","journal-title":"Am J Case Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1601404","article-title":"SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence","volume":"131","author":"Davidson JA","year":"2019","unstructured":"Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad Med. 2019, 131:251-60. 10.1080\/00325481.2019.1601404","journal-title":"Postgrad Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_614_18","article-title":"Fournier's gangrene and sodium-glucose co-transporter 2 (SGLT2) inhibitors: our experience","volume":"23","author":"Dass AS","year":"2019","unstructured":"Dass AS, Immaculate G, Bhattacharyya A. Fournier's gangrene and sodium-glucose co-transporter 2 (SGLT2) inhibitors: our experience. Indian J Endocrinol Metab. 2019, 23:165-6. 10.4103\/ijem.IJEM_614_18","journal-title":"Indian J Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000725","article-title":"Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors","volume":"7","author":"Fadini GP","year":"2019","unstructured":"Fadini GP, Sarangdhar M, De Ponti F, Avogaro A, Raschi E. Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2019, 7:e000725. 10.1136\/bmjdrc-2019-000725","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref27","article-title":"SGLT2 inhibitors and their association with balanoposthitis and Fournier\u2019s gangrene","volume":"22","author":"Seidu S","year":"2020","unstructured":"Seidu S. SGLT2 inhibitors and their association with balanoposthitis and Fournier\u2019s gangrene. Diab Primary Care. 2020, 22:31-2.","journal-title":"Diab Primary Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.920115","article-title":"A case of Fournier's gangrene in a patient taking canagliflozin for the treatment of type II diabetes mellitus","volume":"21","author":"Elbeddini A","year":"2020","unstructured":"Elbeddini A, Gallinger J, Davey M, Brassard S, Gazarin M, Plourde F, Aly A. A case of Fournier's gangrene in a patient taking canagliflozin for the treatment of type II diabetes mellitus. Am J Case Rep. 2020, 21:e920115. 10.12659\/AJCR.920115","journal-title":"Am J Case Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2015.076","article-title":"Evaluation of LRINEC scale feasibility for predicting outcomes of Fournier gangrene","volume":"17","author":"Kincius M","year":"2016","unstructured":"Kincius M, Telksnys T, Trumbeckas D, Jievaltas M, Milonas D. Evaluation of LRINEC scale feasibility for predicting outcomes of Fournier gangrene. Surg Infect (Larchmt). 2016, 17:448-53. 10.1089\/sur.2015.076","journal-title":"Surg Infect (Larchmt)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccm.0000129486.35458.7d","article-title":"The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections","volume":"32","author":"Wong CH","year":"2004","unstructured":"Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004, 32:1535-41. 10.1097\/01.ccm.0000129486.35458.7d","journal-title":"Crit Care Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13989","article-title":"Incorporating simplified Fournier\u2019s gangrene severity index with early surgical intervention can maximize survival in high-risk Fournier\u2019s gangrene patients","volume":"26","author":"Lin TY","year":"2019","unstructured":"Lin TY, Cheng IH, Ou CH, et al.. Incorporating simplified Fournier\u2019s gangrene severity index with early surgical intervention can maximize survival in high-risk Fournier\u2019s gangrene patients. Int J Urol. 2019, 26:737-43. 10.1111\/iju.13989","journal-title":"Int J Urol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-008-9401-4","article-title":"The clinical features of Fournier\u2019s gangrene and the predictivity of the Fournier\u2019s gangrene severity index on the outcomes","volume":"40","author":"Kabay S","year":"2008","unstructured":"Kabay S, Yucel M, Yaylak F, Algin MC, Hacioglu A, Kabay B, Muslumanoglu AY. The clinical features of Fournier\u2019s gangrene and the predictivity of the Fournier\u2019s gangrene severity index on the outcomes. Int Urol Nephrol. 2008, 40:997-1004. 10.1007\/s11255-008-9401-4","journal-title":"Int Urol Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2015.126","article-title":"Neutrophil to lymphocyte and platelet to lymphocyte ratios are more effective than the Fournier\u2019s gangrene severity index for predicting poor prognosis in Fournier\u2019s gangrene","volume":"17","author":"Yim SU","year":"2016","unstructured":"Yim SU, Kim SW, Ahn JH, et al.. Neutrophil to lymphocyte and platelet to lymphocyte ratios are more effective than the Fournier\u2019s gangrene severity index for predicting poor prognosis in Fournier\u2019s gangrene. Surg Infect (Larchmt). 2016, 17:217-23. 10.1089\/sur.2015.126","journal-title":"Surg Infect (Larchmt)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002774","article-title":"Necrotizing soft tissue infection: diagnostic accuracy of physical examination, imaging, and LRINEC score: a systematic review and meta-analysis","volume":"269","author":"Fernando SM","year":"2019","unstructured":"Fernando SM, Tran A, Cheng W, et al.. Necrotizing soft tissue infection: diagnostic accuracy of physical examination, imaging, and LRINEC score: a systematic review and meta-analysis. Ann Surg. 2019, 269:58-65. 10.1097\/SLA.0000000000002774","journal-title":"Ann Surg"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1148\/rg.282075048","article-title":"Fournier gangrene: role of imaging","volume":"28","author":"Levenson RB","year":"2008","unstructured":"Levenson RB, Singh AK, Novelline RA. Fournier gangrene: role of imaging. Radiographics. 2008, 28:519-28. 10.1148\/rg.282075048","journal-title":"Radiographics"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2013.8.18303","article-title":"Diagnosis of necrotizing faciitis with bedside ultrasound: the STAFF Exam","volume":"15","author":"Castleberg E","year":"2014","unstructured":"Castleberg E, Jenson N, Dinh VA. Diagnosis of necrotizing faciitis with bedside ultrasound: the STAFF Exam. West J Emerg Med. 2014, 15:111-3. 10.5811\/westjem.2013.8.18303","journal-title":"West J Emerg Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s40477-014-0106-5","article-title":"A clinical case of Fournier's gangrene: imaging ultrasound","volume":"17","author":"Di Serafino M","year":"2014","unstructured":"Di Serafino M, Gullotto C, Gregorini C, Nocentini C. A clinical case of Fournier's gangrene: imaging ultrasound. J Ultrasound. 2014, 17:303-6. 10.1007\/s40477-014-0106-5","journal-title":"J Ultrasound"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens DL","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al.. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014, 59:e10-52. 10.1093\/cid\/ciu444","journal-title":"Clin Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000158129.56571.05","article-title":"Hyperbaric oxygen for the treatment of Fournier's gangrene","volume":"173","author":"Mindrup SR","year":"2005","unstructured":"Mindrup SR, Kealey GP, Fallon B. Hyperbaric oxygen for the treatment of Fournier's gangrene. J Urol. 2005, 173:1975-7. 10.1097\/01.ju.0000158129.56571.05","journal-title":"J Urol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1177\/1756287216655673","article-title":"Management of equivocal (early) Fournier's gangrene","volume":"8","author":"El-Shazly M","year":"2016","unstructured":"El-Shazly M, Aziz M, Aboutaleb H, et al.. Management of equivocal (early) Fournier's gangrene. Ther Adv Urol. 2016, 8:297-301. 10.1177\/1756287216655673","journal-title":"Ther Adv Urol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000004191","article-title":"Practical review of the current management of Fournier's gangrene","volume":"10","author":"Huayllani MT","year":"2022","unstructured":"Huayllani MT, Cheema AS, McGuire MJ, Janis JE. Practical review of the current management of Fournier's gangrene. Plast Reconstr Surg Glob Open. 2022, 10:e4191. 10.1097\/GOX.0000000000004191","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2337\/cd21-0015","article-title":"Sodium-glucose cotransporter 2 inhibitor use associated with Fournier's gangrene: a review of case reports and spontaneous post-marketing cases","volume":"40","author":"Tran BA","year":"2022","unstructured":"Tran BA, Updike WH, Bullers K, Serag-Bolos E. Sodium-glucose cotransporter 2 inhibitor use associated with Fournier's gangrene: a review of case reports and spontaneous post-marketing cases. Clin Diabetes. 2022, 40:78-86. 10.2337\/cd21-0015","journal-title":"Clin Diabetes"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire DK","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al.. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021, 6:148-58. 10.1001\/jamacardio.2020.4511","journal-title":"JAMA Cardiol"},{"key":"ref45","article-title":"Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes","volume":"40","author":"Ndefo UA","year":"2015","unstructured":"Ndefo UA, Anidiobi NO, Basheer E, Eaton AT. Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. Pharm Ther. 2015, 40:364-8.","journal-title":"Pharm Ther"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20341","article-title":"Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?","volume":"150","author":"Lu H","year":"2020","unstructured":"Lu H, Meyer P, Hullin R. Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?. Swiss Med Wkly. 2020, 150:w20341. 10.4414\/smw.2020.20341","journal-title":"Swiss Med Wkly"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06080616","article-title":"SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome","volume":"12","author":"van Bommel EJ","year":"2017","unstructured":"van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 2017, 12:700-10. 10.2215\/CJN.06080616","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.11.013","article-title":"Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists","volume":"7","author":"Vardeny O","year":"2019","unstructured":"Vardeny O, Vaduganathan M. Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. JACC Heart Fail. 2019, 7:169-72. 10.1016\/j.jchf.2018.11.013","journal-title":"JACC Heart Fail"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00686-z","article-title":"The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit","volume":"10","author":"Patel DK","year":"2019","unstructured":"Patel DK, Strong J. The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Ther. 2019, 10:1771-92. 10.1007\/s13300-019-00686-z","journal-title":"Diabetes Ther"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","volume":"61","author":"Lupsa BC","year":"2018","unstructured":"Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018, 61:2118-25. 10.1007\/s00125-018-4663-6","journal-title":"Diabetologia"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000265","article-title":"Cardiovascular outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis of randomized controlled trials","volume":"28","author":"Malik AH","year":"2020","unstructured":"Malik AH, Yandrapalli S, Goldberg M, Jain D, Frishman WH, Aronow WS. Cardiovascular outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis of randomized controlled trials. Cardiol Rev. 2020, 28:116-24. 10.1097\/CRD.0000000000000265","journal-title":"Cardiol Rev"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13508","article-title":"Fournier's gangrene in a man on empagliflozin for treatment of Type\u00a02 diabetes","volume":"34","author":"Kumar S","year":"2017","unstructured":"Kumar S, Costello AJ, Colman PG. Fournier's gangrene in a man on empagliflozin for treatment of Type\u00a02 diabetes. Diabet Med. 2017, 34:1646-8. 10.1111\/dme.13508","journal-title":"Diabet Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12896","article-title":"Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes","volume":"11","author":"Onder CE","year":"2019","unstructured":"Onder CE, Gursoy K, Kuskonmaz SM, Kocer U, Culha C. Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes. J Diabetes. 2019, 11:348-50. 10.1111\/1753-0407.12896","journal-title":"J Diabetes"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000985","article-title":"Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene","volume":"8","author":"Yang JY","year":"2020","unstructured":"Yang JY, Wang T, Pate V, Buse JB, St\u00fcrmer T. Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene. BMJ Open Diabetes Res Care. 2020, 8:10.1136\/bmjdrc-2019-000985","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2020.16.2.113","article-title":"Cardiorenal syndrome in type 2 diabetes mellitus - rational use of sodium-glucose cotransporter-2 inhibitors","volume":"16","author":"Kalra S","year":"2020","unstructured":"Kalra S, Aydin H, Sahay M, et al.. Cardiorenal syndrome in type 2 diabetes mellitus - rational use of sodium-glucose cotransporter-2 inhibitors. Eur Endocrinol. 2020, 16:113-21. 10.17925\/EE.2020.16.2.113","journal-title":"Eur Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/101704-fourniers-gangrene-a-coexistence-or-consanguinity-of-sglt-2-inhibitor-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:32Z","timestamp":1707507452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/101704-fourniers-gangrene-a-coexistence-or-consanguinity-of-sglt-2-inhibitor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":55,"URL":"https:\/\/doi.org\/10.7759\/cureus.27773","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,8]]}}}